Personalised growth evaluation

Responses to growth hormone (GH) treatment vary widely. There is a broad range of sensitivity — and responsiveness — to GH, so a ‘one size fits all’ approach to GH treatment is no longer appropriate. The challenge for endocrinologists is how to optimise GH treatment with respect to growth, safety and cost for each child.

Add patientiGRO is a web-based medical device that supports personalised growth evaluations to help you deliver personalised treatment that optimises response to growth hormone (GH) treatment. This allows you to evaluate a child’s potential to respond to GH treatment before it is initiated. This includes expected height velocities (mean and range) from the start of treatment based on a child’s unique combination of baseline characteristics and the given GH dose.

Supported by iGRO, you can give patients and their families realistic expectations of short and long-term growth outcomes. And, monitor the effect of GH treatment by comparing a child’s predicted and actual growth responses to GH each year.


To do this, iGRO requires standard data that is routinely collected during clinic visits.

 

 

 

iGRO calculates growth predictions using data typically collected during routine clinical practice

 

 

Using iGRO you can evaluate

IoR

      Index of responsiveness (IoR) after the first 12 months of GH treatment

      Distance to target height vs. age

      GH dose relative to age

      Maximum GH peak or weight standard deviation score (SDS) relative to age

 

HV: height velocity, MPH: mid parental-height, SDS: standard deviation score

 

 

 

 

Evaluations of growth response can be used to guide treatment decisions.

Growth Response evaluation

iGRO provides the information you need to identify discrepancies between predictions and actual response. You can then investigate causes such as non-adherence, where additional support can be offered, and the presence of additional diseases, which may have therapeutic consequences.

 

1 - Kaspers S et al Implications of a data-driven approach to treatment with growth hormone in children with growth hormone deficiency and Turner syndrome. Appl Health Econ Health Policy 2013;11:237–49.